DISCLAIMER: The content of this presentation may not accurately reflect current legal or regulatory requirements, industry standards, or professional best practices. ISMPP is providing access to this presentation as a member service only, and does not recommend or condone the use of this presentation in whole or in part to support legal or professional decisions or practices.

# Whither the Ingelfinger rule? An editor's perspective

Dr Trish Groves Deputy editor, BMJ tgroves@bmj.com



# The problem

The Food and Drug Amendments Act 2007 requires pharmaceutical companies to register nearly all trials and to disclose their results publicly within a timeframe dictated by the new legislation or pay penalties of \$10K a time

Will this infringe the Ingelfinger rule and make it impossible to publish trials in medical journals?



# What results have to be disclosed for FDA?

Four tables:

- demographic and baseline data collected overall and for each arm of the trial, including patients dropped out and excluded from analysis
- raw data and stats tests for each of the primary and secondary outcome measures for each arm of the trial
- anticipated and unanticipated serious adverse events grouped by organ system, with number and frequency of such event in each arm of the clinical trial
- anticipated and unanticipated adverse events exceeding 5% frequency in any arm of the trial, grouped by organ system



# What I aim to cover

- International Committee of Medical Journal Editors (ICMJE) policy
- BMJ policy
- what investigators and authors need to know to continue publishing clinical trial results in top-tier journals and comply with the new law



# **ICMJE policy**

ICMJE said in June 2007 that member journals \* will not consider results posted in a clinical trials register as previous publications if presented in the form of a brief, structured (<500 words) abstract or table.

ICMJE meets next in May: will this policy change to cover FDAA's required four tables?

\* Annals of Internal Medicine, BMJ, Canadian Medical Association Journal, Croatian Medical Journal, JAMA, Nederlands Tijdschrift voor Geneeskunde, New England Journal of Medicine, New Zealand Medical Journal, The Lancet, The Medical Journal of Australia, Tidsskrift for Den Norske Llegeforening, and Ugeskrift for Laeger



# **ICMJE left door open**

"... We recognise that the climate for results registration will probably change dramatically and unpredictably over coming years. For the present, the ICMJE will not consider results posted in the same primary clinical trials register in which the initial registration resides as previous publications if the results are presented in the form of a brief, structured (<500 words) abstract or table..."



# **BMJ policy - history**

- 1997 BMJ was one of 100 journals offering amnesty for unreported trials (but only165 trials in first year)
- 1999 BMJ called for registration in any of the many burgeoning registers
- 2004 BMJ supported ICMJE rules on compulsory trial registration but disagreed with criterion that registers had to be not for profit, which only clinicaltrials.gov then met
- 2006 BMJ supported WHO's International Clinical Trials Registry Platform (ICTRP)




# **Precedents at BMJ**

BMJ believes the Ingelfinger rule is outdated, and does not consider these to preclude journal publication:

- research presented at scientific meetings
- research published in non-English languages and/or for limited audiences
- systematic reviews and meta-analyses conducted for and posted by:
  - Cochrane Library
  - UK Health Technology Assessment Agency







## ③ · ③ · ▲ ② ⑤ / ○ ☆ Ø ② · ▲ ◎ · □ ↓ ∅ &

Related Articles Find this article in its weekly table of contents

Conclusions Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects.

### Introduction

Obesity and overweight are highly and increasingly prevalent chronic conditions currently affecting over 1.1 billion individuals worldwide and are associated with premature mortality, chronic morbidity, and increased healthcare use.<sup>1,2</sup> Recently published guidelines recommend lifestyle modification as the initial treatment for obesity and suggest that adjunctive drug treatment is considered in patients with a body mass index≥30 or 27-29.9 with medically complicated obesity.<sup>2</sup> Orlistat, a gastrointestinal lipase inhibitor, sibutramine, a centrally acting monoamine reuptake inhibitor, and rimonabant, an endocannabinoid receptor antagonist, are approved for long term treatment of obesity (one year or more).<sup>3</sup>


Treatment with anti-obesity drugs is common, with global sales in 2005 estimated at \$1.2bn.<sup>4</sup> As weight losses achieved with lifestyle intervention are modest and limited by high rates of recidivism and compensatory slowing of metabolism,<sup>5 6</sup> there is potential for even greater use of drug treatment. Furthermore, as the prevalence and incidence of obesity grow and as newer agents are developed, use of these drugs will probably increase further.

We carried out an updated systematic review and meta-analysis to quantify the efficacy of and adverse effects associated with the long term use of antiobesity drugs. This paper is a summary of a recently updated Cochrane collaboration systematic review.<sup>7</sup>

## Methods

#### Inclusion and exclusion criteria and outcomes

With the help of a medical librarian we searched Medline, Embase, the **Cochrane** controlled trials register, and the metaregister of controlled trials (www.controlled-trials.com) from December 2002 to December 2006 and examined reference lists of identified articles. In the original version of this review, the search covered the period from the inception of each database to December 2002.<sup>8</sup> We searched for placebo controlled clinical trials of at least one year in duration that evaluated the effects of anti-obesity drugs on weight, cardiovascular risk factors, cardiovascular morbidity and mortality, and overall mortality. A subgroup analysis examined weight loss and glycaemic control in patients with type 2 diabetes. All trials had to be double blind (patient and care provider) randomised controlled trials examining overweight or obese adults





🐴 Error on page.

G · 🕞 · 🗷 🖻 🏠	P 🛧 🥴 🙆 - 🥘 🛍 🦓
<u> ۷ Viley InterScience home</u>	→ My Profile → Log In
	About Cochrane   Access to Cochrane   For Authors   Help   P Save Title to My Profile
	eviews   Updated Reviews   A-Z   By Review Group Clinical Trials   Methods Studies   Technology Assessments   Economic Evaluations 2 More Info Advanced Search   MeSH Search   Search History   Saved Searches
[Review] Long-term pharmacotherapy for obesity and overweight	[Review] Long-term pharmacotherapy for obesity and overweight RPadwal, SK Li, DCW Lau
PDF (Size 554K)  • Abstract • Plain language summary • Background	<ul> <li>Cochrane Database of Systematic Reviews 2007 Issue 4</li> <li>Copyright © 2007 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd.</li> <li>DOI: 10.1002/14651858.CD004094.pub2 This version first published online: 20 October 2003 in Issue 4, 2003</li> <li>Date of Most Recent Substantive Amendment: 20 August 2003</li> <li>This record should be cited as: Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004094. DOI: 10.1002/14651858.CD004094.pub2.</li> </ul>
<ul> <li>Objectives</li> <li>Criteria for considering studies for this review</li> </ul>	Abstract
<ul> <li>Search methods for identification of studies</li> <li>Methods of the review</li> <li>Description of studies</li> <li>Methodological quality</li> </ul>	Background Worldwide prevalence rates of obesity and overweight are rising and safe and effective treatment strategies are urgently needed. A number of anti-obesity agents have been studied in short-term clinical trials, but long-term efficacy and safety need to be established.
Results     Discussion	<b>Objectives</b> To assess/compare the effects and safety of approved anti-obesity medications in clinical trials of at least one-year duration.
<ul> <li>Authors' conclusions</li> <li>Potential conflict of interest</li> <li>Acknowledgements</li> </ul>	Search strategy MEDLINE, EMBASE, the Cochrane Controlled Trials Register (CENTRAL), the Current Science Meta-register of Controlled Trials, and reference lists of original studies and reviews were searched. Date of last search was December 2002. Drug
ê 🛛	Internet 🔮



# **Tips for BMJ authors - before submitting article**

- see <u>http://resources.bmj.com/bmj/authors</u>
- presubmission enquiry
  - contact the research editor <u>tgroves@bmj.com</u> +44
     207 383 6018
  - email the abstract or at least describe the research question and study design
  - explain what the work adds to knowledge
  - say when results will be/were disclosed for FDA
- if results not yet disclosed and you're seeking publication at same time as FDA posting, request fast track review



# **Tips for BMJ authors – fast track review**

See <u>http://resources.bmj.com/bmj/authors/fast-track-</u> publication

- yes or no reply in 24 hours to fast track request
- if fast tracked we externally peer review and discuss within one week at editorial meeting, with decision within 24 hours of that meeting
- if provisionally accepted we expect you to revise the manuscript within 48 hours
- we edit the accepted manuscript rapidly and request proofs back within 24 hours
- we aim to fully publish fast tracked articles within four weeks of submission



## **Tips for BMJ authors - when submitting article**

- all articles fast track and normal track handled at our online editorial office <u>http://submit.bmj.com</u>
- in cover letter
  - say what's already been or is soon to be disclosed or published
  - explain how the article would differ from/add to it
  - repeat this information even if discussed before submission: a different editor may handle the article
- as supplemental files
  - upload any previously disclosed versions



# But...

BMJ gives priority to articles that help doctors make better decisions. So we're interested in trials:

- where intervention goes head to head against best current treatment, rather than placebo
- of new indications and drugs rather than me-toos
- with adequate doses of intervention and control drugs
- with clinically important outcomes including harms
- that show no benefit as long as there's sufficient power and important/relevant outcomes
- that are relevant enough to a wide range of doctors



Thank you

Trish Groves tgroves@bmj.com

